Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
February 23, 2015
Monday’s RegMed rhythms: overbought versus oversold can be a daily infliction
February 23, 2015
Cesca Therapeutics (KOOL) 2 Executives relinquish share awards
February 19, 2015
RegMed's buying pressure will not let prices fall as low as the previous low
February 17, 2015
Tuesday’s RegMed rhythms: the paradox of a good day, it will soon end
February 17, 2015
Cesca (KOOL) Q4/14 Earnings: LOSS UP +25%, LPS UP +27%
February 17, 2015
Lower open expected; RegMed’s earnings start racking-up, be ready for leaner gains and excessive losses
February 11, 2015
Wednesday’s RegMed rhythms: every other day herd mentality stifles pricing
February 11, 2015
Cesca Therapeutics (KOOL) Approval of MarrowXpress™ System in India - BUY
February 6, 2015
RegMed’s equities close down paced by risk on/off tolerance
February 5, 2015
RegMed’s UP structurally but, not conditionally – waiting for sustainable entry pricing
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.